⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BIIB News
Biogen Inc. Common Stock
Cell Viability Assays Market to Reach US$3.8 Billion by 2034 as Drug Discovery and Diagnostics Demand Accelerates
globenewswire.com
TMO
BIO
BIIB
DHR
AVTR
BDX
Duchenne Muscular Dystrophy Treatment Market Report (2025-2034) Published, Segments Intravenous, Subcutaneous, and Oral Routes Across Three Pharmacy Channels
globenewswire.com
SRPT
PFE
BIIB
REGN
GILD
JNJ
ABBV
NVS
SNY
CAPR
SLDB
WVE
EDIT
Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide
prnewswire.com
BIIB
Biogen Appoints Michael J. Parini as Chief Legal Officer
globenewswire.com
BIIB
Tuberculosis Clinical Trial Pipeline Shows Potential with Active Contributions from 28+ Key Companies | DelveInsight
globenewswire.com
FMS
BIIB
MDT
NVO
LLY
AZN
RDNT
LXRX
SNY
XRTX
RGEN
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
globenewswire.com
BIIB
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
prnewswire.com
BIIB
Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
globenewswire.com
BIIB
FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease
prnewswire.com
BIIB
FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease
globenewswire.com
BIIB